Brussels, Belgium

Anne Michel

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Parkinson's Disease Treatment by Anne Michel

Introduction

Anne Michel is a prominent inventor based in Brussels, Belgium. She has made significant contributions to the field of medicine, particularly in the treatment of Parkinson's disease. Her innovative approach combines the use of specific pharmaceutical agents to enhance therapeutic outcomes for patients suffering from this debilitating condition.

Latest Patents

Anne Michel holds a patent for her invention titled "Methods for treating Parkinson's disease." This patent describes a method of treating Parkinson's disease in mammals by administering a first pharmaceutical agent, which is an antagonist of the adenosine receptor 2 (A), alongside a second pharmaceutical agent that acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B. This dual approach aims to improve the efficacy of treatment for patients.

Career Highlights

Throughout her career, Anne has demonstrated a strong commitment to advancing medical science. Her work at UCB Biopharma Sprl has positioned her as a key player in the pharmaceutical industry. With her innovative mindset, she continues to explore new avenues for improving patient care and treatment methodologies.

Collaborations

Anne collaborates with notable colleagues such as Patrick Downey and Florian Montel. Their combined expertise fosters a dynamic environment for research and development, leading to groundbreaking advancements in the treatment of neurological disorders.

Conclusion

Anne Michel's contributions to the treatment of Parkinson's disease exemplify the impact of innovation in medicine. Her patented methods represent a significant step forward in enhancing the quality of life for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…